Oral anticoagulation in end-stage CKD and atrial fibrillation
Ranokhon IgamberdievaTashkent Pediatric Medical Institute, Tashkent, UzbekistanSherzod AbdullaevTashkent Pediatric Medical Institute, Tashkent, Uzbekistan | Republican specialized scientific-practical center of nephrology and kidney transplantation
ABI
Abstract
Leading cardiovascular diseases (arterial hypertension, coronary heart disease and diabetes mellitus) are often accompanied by such complications as atrial fibrillation (AF) and chronic kidney disease (CKD). As kidney function worsens, the risk of AF increases. The incidence of AF and CKD ranges from 5:1. At the same time, the risk of developing of end-stage CKD (ESCKD) increases in patients with AF. The combination of AF and ESCKD, on the one hand, increases the risk of thromboembolic complications, and on the other hand, it can cause hemorrhagic complications, which makes it difficult to decide whether to start oral anticoagulant therapy.
Topics
Identifiers
Citations and references
Cited by 010 references